RxDoctor Payments Data

Zahra Afshari, MD

Neurology · Glenview, ILNPI 1508983628

Payments from drug & device makers

$22,038in general payments, 2019–2025

Across 1,036 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Neurocrine Biosciences, Inc.$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • Lundbeck LLC$1K
  • Acadia Pharmaceuticals Inc$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$5002%
  • Food & beverage$21,29197%
  • Education$2481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)128$2,667
UCB, Inc.65$1,629
Neurocrine Biosciences, Inc.56$1,550
Supernus Pharmaceuticals, Inc.86$1,406
Lundbeck LLC65$1,133
Acadia Pharmaceuticals Inc37$1,001
Teva Pharmaceuticals USA, Inc.29$869
Lilly USA, LLC37$797
Pfizer60$794
Amneal Pharmaceuticals LLC33$741
Biogen40$735
Eisai Inc.36$723
Acorda Therapeutics, Inc26$564
MDD US Operations, LLC23$528
Takeda Pharmaceuticals U.S.A., Inc.26$457
SK Life Science, Inc.21$454
Alnylam Pharmaceuticals Inc.19$421
Genentech USA, Inc.16$398
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$385
Otsuka America Pharmaceutical, Inc.13$364
Biohaven Pharmaceutical Holding Company Ltd.18$339
Novo Nordisk18$268
Idorsia Pharmaceuticals US Inc8$257
Axsome Therapeutics, Inc.12$252
Tanabe Pharma America, Inc.11$251
Amgen8$250
Upsher-smith Laboratories LLC16$237
Biohaven Pharmaceuticals, Inc.9$154
Jazz Pharmaceuticals Inc.8$146
Argenx US, Inc.2$144
Kyowa Kirin, Inc.5$125
Tonix Medicines, Inc.5$113
Abbott3$108
Sumitomo Pharma America, Inc.4$97
Banner Life Sciences, LLC4$88
AstraZeneca(2 entities)3$83
ANI Pharmaceuticals, Inc.3$80
Alfasigma USA, Inc.5$75
Assertio Therapeutics, Inc.3$67
Avanir Pharmaceuticals, Inc.4$67
Catalyst Pharmaceuticals, Inc.2$66
Xeris Pharmaceuticals, Inc.3$63
Johnson & Johnson2$58
Vertical Pharmaceuticals, LLC3$55
GSK1$55
Novartis3$54
Cala Health, Inc.3$54
Avion Pharmaceuticals3$53
Corium, LLC3$53
Merz Pharmaceuticals, LLC2$50
Promius Pharma LLC2$47
Currax Pharmaceuticals LLC3$45
Mallinckrodt Hospital Products Inc.2$44
Amarin Pharma, Inc.2$41
Impel Pharmaceuticals Inc.2$40
ITF Therapeutics LLC1$36
Madrigal Pharmaceuticals1$33
Biomarin Pharmaceutical Inc.2$33
C2n Diagnostics, LLC1$31
Aucta Pharmaceuticals, Inc.2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,038 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$222,474
Medicare patients
166
Services billed
2,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate44$265,869
VraylarCariprazine Hcl12$34,764
Rivastigmine60$10,113
Memantine Hcl141$4,085
Duloxetine Hcl75$3,750
Donepezil Hcl118$1,797
Pregabalin16$1,767
Gabapentin110$1,726
Escitalopram Oxalate62$1,307
Quetiapine Fumarate14$973
Carbidopa-LevodopaCarbidopa/Levodopa42$677
Mirtazapine53$623
Fluoxetine Hcl23$619
Amitriptyline Hcl26$605
Topiramate21$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$1,001$265,86944 claims
AbbVieVraylar$2,667$34,76412 claims
Upsher-smith Laboratories LLCTopiramate$237$43321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.

Other neurology in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →